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PURPOSE. To detect visual field (VF) progression by analyzing spatial pattern changes.
METHODS. We selected 12,217 eyes from 7360 patients with at least five reliable 24-2 VFs and 5
years of follow-up with an interval of at least 6 months. VFs were decomposed into 16
archetype patterns previously derived by artificial intelligence techniques. Linear regressions
were applied to the 16 archetype weights of VF series over time. We defined progression as
the decrease rate of the normal archetype or any increase rate of the 15 VF defect archetypes
to be outside normal limits. The archetype method was compared with mean deviation (MD)
slope, Advanced Glaucoma Intervention Study (AGIS) scoring, Collaborative Initial Glaucoma
Treatment Study (CIGTS) scoring, and the permutation of pointwise linear regression
(PoPLR), and was validated by a subset of VFs assessed by three glaucoma specialists.
RESULTS. In the method development cohort of 11,817 eyes, the archetype method agreed
more with MD slope (kappa: 0.37) and PoPLR (0.33) than AGIS (0.12) and CIGTS (0.22). The
most frequently progressed patterns included decreased normal pattern (63.7%), and
increased nasal steps (16.4%), altitudinal loss (15.9%), superior-peripheral defect (12.1%),
paracentral/central defects (10.5%), and near total loss (10.4%). In the clinical validation
cohort of 397 eyes with 27.5% of confirmed progression, the agreement (kappa) and accuracy
(mean of hit rate and correct rejection rate) of the archetype method (0.51 and 0.77)
significantly (P < 0.001 for all) outperformed AGIS (0.06 and 0.52), CIGTS (0.24 and 0.59),
MD slope (0.21 and 0.59), and PoPLR (0.26 and 0.60).
CONCLUSIONS. The archetype method can inform clinicians of VF progression patterns.
Keywords: visual field progression, visual field patterns, unsupervised artificial intelligence
The 24-2 pattern visual field (VF) measured by standardautomated perimetry1,2 is predominantly used for diagnos-
ing glaucoma and monitoring its progression.3–5 Given large VF
test-retest variability, including short-term and long-term
fluctuations,6–8 detecting VF progression is a challenge for
glaucoma management.9 Numerous methods and criteria have
been developed for determining VF progression in glauco-
ma.4,5,10–15 In general, current VF progression detection
methods can be divided into clinician-based evaluation and
computer-based algorithms.9,16,17
The clinician-based methods generally involve the manual
subjective review of VF series.18–20 Inevitably, such methods
typically have low interrater agreement as reported due to their
subjectivity.18,19,21
The computer-based algorithms to detect VF progression
can be grouped into event-based and trend-based meth-
ods.9,16,17 The Advanced Glaucoma Intervention Study (AGIS)
criteria,4 the Collaborative Initial Glaucoma Treatment Study
(CIGTS) criteria,5 and Guided Progression Analysis (GPA)14
represent three well-known event-based methods. AGIS devel-
oped a dedicated defect score, calculated based on sector-
weighted total deviation, and defined progression as three
consecutive VFs with a defect score worsening of at least four
units compared with baseline.4,15 CIGTS developed a similar
defect score, calculated based on sector-weighted total
deviation probability, and defined VF progression as three
consecutive VFs with a defect score worsening of three units or
more compared with baseline.5,15 Similarly, the GPA defines
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progression as two or three consecutive VFs with at least three
identical worsening locations compared with baseline; the
worsening at a single location is determined as the deteriora-
tion of pattern deviation values in the follow-ups exceeding
outside of the 95% confidence interval for expected test-retest
variability in stable glaucoma patients.9,14,16,17 The proprietary
GPA is derived from the Early Manifest Glaucoma Trial
protocol.22,23
Trend-based methods analyze VF series using linear
regression models and the slope of VF measures over time;
its associated P value is used to define a progression detection
threshold. Global measures including mean deviation
(MD)10,24–28 and VF index12,16,17 are widely used for trend-
based progression analysis due to their simplicity of imple-
mentation and interpretation. Alternatively, local measures
using total deviation at individual test locations also were
introduced to detect VF progression with linear regression,
termed pointwise linear regression (PLR).13 The most
commonly used PLR criteria define VF progression as at least
1 dB per year change in total deviation for at least two or
three locations with a P value for the regression of less than
0.05 or 0.01.29 Varying PLR methods have been developed to
improve the detection performance.29–31 Compared with
global measures, location-based methods can potentially
increase the sensitivity of VF progression detection because
glaucomatous progression is highly location specific. This
increase in sensitivity comes with a sacrifice of specifici-
ty.32–34
Tracking the progression of patterns by alternative com-
puter-based algorithms based on artificial intelligence tech-
niques has been previously attempted.35–37 For instance, a
technique called variational Bayesian independent component
analysis has been applied,35 which identifies major axes inside
the VF data space. VF series of glaucoma patients were
decomposed into the VF axis patterns and the coefficients of
each VF axis pattern were regressed by follow-up time.
Progression was defined as regression slopes of VF axis
patterns exceeding the 95% confidence limits of pattern slopes
in stable eyes. In most cases, the VF axis patterns do not
resemble typical glaucomatous VF loss patterns,35–37 limiting
the utility of tracking progression.
To enhance computerized VF progression detection strate-
gies, we applied an unsupervised artificial intelligence
technique that determines representative patterns on the
corners of the data space, namely archetypal analysis,38,39
which explicitly emphasizes distinctive features of the data. We
previously applied this method to a clinical VF data set and
mathematically identified 16 representative VF patterns (ar-
chetypes),40 which resemble clinically recognizable patterns of
VF loss.41 Eleven of the 16 patterns bear typical features of
retinal nerve fiber defects, which was confirmed by a clinical
correlation study.42 The glaucomatous VF archetypes were
then successfully applied to improve the diagnostic accuracy of
the Glaucoma Hemifield Test.43
In this work, we use these previously determined 16
archetypes to track VF progression. In addition to determining
whether a VF series progresses or not, similar to most previous
progression detection methods, we also aim to distinguish and
quantify pattern-specific aspects of VF progression in glaucoma
over time.
METHODS
The VF data used in this study were collected and managed by
the Glaucoma Research Network, a consortium composed of
glaucoma services from Massachusetts Eye and Ear, Wilmer Eye
Institute, New York Eye and Ear Infirmary, Bascom Palmer Eye
Institute, and Wills Eye Hospital. The institutional review
boards of each ophthalmic center approved this retrospective
cohort study. This study complies with all principles of the
Declaration of Helsinki.
Participants and Data
We included reliable VFs from our large dataset of Swedish
Interactive Thresholding Algorithm Standard 24-2 VFs mea-
sured with the Humphrey Field Analyzer II (Carl Zeiss Meditec,
Dublin, CA). The inclusion criteria were fixation loss 33%,
false-negative rates 20%, and false-positive rates 20%.24,44–48
We further selected eyes meeting the following criteria for
our progression analyses: at least five reliable VF measure-
ments, at least 5 years of follow-up, and the time between each
VF of 6 months or more.
The Archetype Method for Progression Detection
Figure 1A shows the 16 representative VF patterns (arche-
types) in glaucoma we previously determined by archetypal
analysis,40 based on the total deviation values of more than
13,000 VFs. Any VF test can be represented as the summation
of the 16 archetypes multiplied by their respective coeffi-
cients (the sum of the 16 coefficients is normalized to 1), as
illustrated in Figure 1B. The clinical descriptions of each
archetype are also denoted in Figure 1A. Archetype 1
represents a normal VF, and all other archetypes represent
various VF defects, including a superior peripheral defect
(archetype 2), superonasal and inferonasal steps (archetypes
3 and 5), a temporal wedge (archetype 4), a near total loss
pattern (archetype 6), a central scotoma (archetype 7),
superior and inferior altitudinal defects (archetypes 8 and
13), inferotemporal and inferonasal defects (archetypes 9 and
10), a concentric peripheral defect (archetype 11), temporal
and nasal hemianopia (archetypes 12 and 15), as well as
predominately superior and inferior paracentral defects
(archetypes 14 and 16).
The flowchart in Supplementary Figure S1 describes the
overall procedure and algorithm for archetype progression
detection, which are elaborated here. The VF series of total
deviation values for each eye was decomposed into the 16
archetypes by publicly available decomposition software
(Supplementary Material).40 Linear regression was used to
analyze the changes of the 16 archetype coefficients over time.
Sixteen slopes {bi}i¼1:16 were extracted for progression
detection. The limit of archetype slope variation due to long-
term fluctuation was used as the slope threshold bt to detect
progression. The slope threshold bt was calculated as the
average of the absolute value of 2.5% and 97.5% percentiles
over all 16-slope distributions in this dataset, which is
approximately equivalent to a 5% significance level commonly
used in the practice of statistics. The threshold bt was
calculated as the absolute average of the lower and upper
tails, because even if a VF series shows progression, some
individual archetypes can be regressing, as all 16 archetype
decomposition coefficients sum to 1, as constrained by the
archetype algorithm.
If the slope for archetype 1 (b1) is less than or equal tobt,
that is, the normal VF archetype decreases substantially, or
any of the slopes for other archetypes ({bi}i¼2:16) is greater
than or equal to bt (i.e., the abnormal archetypes increase
substantially), the archetype method will indicate progression
and generate the progressed archetype(s). Otherwise, the
algorithm will label the VF series as nonprogressing and
provide the most worsening archetypes for the clinician’s
information.
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FIGURE 1. Illustration of VF pattern decomposition with archetypes: (A) the 16 computationally derived archetypes and (B) an example of the VF
decomposition to the VF archetypes. AT, archetype. See more details in the works by Elze and coworkers40 and Wang and coworkers.43
AI Approach to Detect Visual Field Progression in Glaucoma IOVS j January 2019 j Vol. 60 j No. 1 j 367
Downloaded from iovs.arvojournals.org on 02/06/2019
Established Methods for Progression Detection
We implemented four computational progression methods in
our dataset, including two event-based and two trend-based
methods, to compare with our new algorithm. The two event-
based methods are the AGIS and the CIGTS scoring methods.
The two trend-based methods are the MD slope method and
the PoPLR.
Clinical Validation
The VF series of 400 eyes from Massachusetts Eye and Ear
were randomly selected and separated from the larger cohort
used to develop the archetype method. Three glaucoma
specialists (LQS, PP, and LRP) masked to the results by all
computational methods manually assessed these VF series for
progression. The criteria for clinical assessment accounted for
event-based and trend-based progression. Pattern deviation
plots were divided into six peripheral (superior and inferior
nasal step and superior and inferior Bjerrum areas) and two
paracentral regions.49 In each peripheral region, a VF defect is
defined as a cluster of at least three adjacent test points
conforming to nerve fiber layer topology with5 dB or worse
for each point. For the paracentral region, a VF defect is
defined as at least two adjacent points with a sum of15 dB or
more. If the final VF in the series shows no VF defect in all
regions, the status was no progression. Progression was
defined in three ways: event-based progression is the presence
of a VF defect in one or more regions in the final VF,
reproduced on a prior VF but not seen in the baseline VF;
trend-based progression occurs when a VF defect present in
one or more regions on the final two VFs is worse than the first
two tests (average pattern deviation [PD] value for all test
points in the region worsened by3 dB or more) or when the
average MD values of the final two VFs was worse by3 dB or
more than the average of the first two VFs. A VF series can have
both event-based (VF defect in a new region) and trend-based
(VF defect worsening in another region) progression. Uncon-
firmed progression was defined as VF defect(s) present only on
the final VF. Two of the three glaucoma specialists listed above
reviewed each VF series together. Senior glaucoma specialists
(LQS and LRP) reviewed all disagreement cases to reach
unanimous decisions.
Statistical Analyses
The concordance between the archetype method and the
established progression algorithms was evaluated by Kappa
coefficient (Cohen’s kappa50 for comparing paired progression
methods, Fleiss’ kappa51 for comparing more than two
progression methods). The concordances between clinician
evaluation and our archetype method as well as the four
existing methods were assessed by Cohen’s kappa coefficient.
For the VFs used for clinician evaluation, hit rate and correct
rejection rate were used to determine the detection accuracy
of our archetype method in comparison with the four existing
progression detection methods.
RESULTS
A total of 11,817 eyes were used for the archetype method
development and 400 eyes were reserved for clinical valida-
tion. The Table shows the statistical summary of the method
development and clinical validation cohorts. The clinical
validation cohort had significantly (P < 0.001 for all) better
MD, younger age, shorter follow-up time, and smaller number
of VFs. The percentiles of 0%, 2.5%, 5%, 25%, 50%, 75%, 95%,
97.5%, and 100% for each archetype slope at different
percentiles can be found in Supplementary Table S1. The
slope threshold to assess progression was determined as 0.025
per year as the average of the absolute value of the 2.5% and
97.5% percentiles over the entire slope distribution (See
Supplementary Table S1).
The archetype method detected progression in 35.0% of the
eyes, whereas the percents of progressed eyes were 4.0%,
9.5%, 20.5%, and 12.4% by AGIS, CIGTS, MD slope, and PoPLR
methods, respectively (Supplementary Fig. S2a). The progres-
sion detection by the archetype method was in fair agreement
(Supplementary Fig. S2b) with CIGTS scoring (kappa: 0.22),
MD slope (0.37), and PoPLR (0.33, P < 0.001 for all three
methods), and was in slight agreement with AGIS scoring
(kappa: 0.12, P < 0.001). The kappa coefficient among the four
existing methods was 0.43 (P < 0.001), which was in moderate
agreement.
In addition to progression status, the archetype method also
yielded patterns of progression. Up to five progression patterns
were detected per eye, with more than 99% of eyes with three
or fewer progression patterns (Fig. 2A); 63.7 % of eyes
progressed based on decreased coefficient of archetype 1
(the normal VF pattern) with a slope  0.025 per year (Fig.
2B). The other archetypes (VF defect patterns) in frequently
progressed patterns evidenced by an increase in a slope
‡0.025 per year were superior-peripheral defect (archetype 2,
12.1%), superonasal step (archetype 3, 10.2%), inferonasal step
(archetype 5, 6.2%), central scotoma (archetype 7, 4.4%),
superior paracentral defect (archetype 14, 6.1%), superior
altitudinal loss (archetype 8, 11.5%), inferior altitudinal loss
(archetype 13, 4.4%), and near total loss (archetype 6, 10.4%).
Clinical Validation Results
A separate cohort of 400 eyes was used for clinical validation,
although 3 eyes were further excluded due to fewer than five
reliable VFs available for clinical review. Clinician evaluation
determined progression in 131 (33.0%) eyes. Specifically, 45
eyes (11.3%) progressed by event, 33 eyes (8.3%) by trend, and
31 eyes (7.8%) by both event and trend; 22 eyes (5.6%) had
unconfirmed progression by event.
The archetype method showed significantly higher agree-
ment (kappa 0.48) with the clinician evaluation than any of the
four existing methods (Fig. 3). The kappa coefficients of the
four existing methods were 0.05, 0.19, 0.18, and 0.21 for AGIS,
CIGTS, MD slope, and PoPLR, respectively. When eyes with
unconfirmed progression were excluded, all progression
algorithms were more concordant (P < 0.001 for all, t-test














Method developing cohort 11,817 7.6 6 2.0 6.7 6 1.8 63.8 6 12.7 4.1 6 5.2 5.7 6 6.3
Clinical validation cohort 397 6.3 6 0.9 6.0 6 1.0 60.6 6 13.5 2.3 6 2.8 3.6 6 4.1
P value of group difference <0.001* <0.001* <0.001* <0.001* <0.001* <0.001*
Values are expressed as mean 6 SD.
* P values that are significant (P < 0.05).
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with bootstrapping) with the clinician evaluation. The
agreement between the archetype method and clinician
evaluation remained highest with kappa of 0.51.
The archetype method showed a hit rate of 0.66 and correct
rejection rate of 0.82 for detecting progression in eyes with
progression by clinician evaluation (Fig. 4). The hit rate
increased to 0.72, when eyes with unconfirmed progression
were excluded. The hit rate of the archetype method to detect
confirmed progression was significantly higher (P < 0.001, t-
test with bootstrapping) than AGIS (0.05), CIGTS (0.20), MD
slope (0.26), and PoPLR (0.20). In comparison, the correct
rejection rate of the archetype method (0.82) was significantly
lower (P < 0.001, t-test bootstrapping) than AGIS (1.0), CIGTS
(0.98), MD slope (0.92), and PoPLR (1.0). The archetype
method outperformed all four existing methods in terms of
overall accuracy measured by the mean of hit rate and correct
rejection rate. The mean of hit rate and correct rejection rate of
the archetype method (0.74 with unconfirmed progressions
and 0.77 without unconfirmed progression) were significantly
higher (P < 0.001 for all, bootstrapping) than AGIS (0.52 and
0.52), CIGTS (0.58 and 0.59), MD slope (0.58 and 0.59), and
PoPLR (0.58 and 0.60, respectively).
We also assessed the hit rates and correct rejection rates for
mild (MD ‡ 6 dB) and moderate (12 dB  MD < 6 dB)
glaucoma separately. The hit rate in mild glaucoma (0.68) by
the archetype method was significantly higher (P¼0.002) than
in moderate glaucoma (0.61). The hit rates in mild glaucoma by
CIGTS and PoPLR (0.16 for both) were significantly (P¼ 0.002
and 0.007) lower than in moderate glaucoma (0.22 for both).
The correct rejection rate in mild glaucoma (0.82) by the
archetype method was significantly higher (P ¼ 0.02) than in
moderate glaucoma (0.76). The correct rejection rates in mild
glaucoma by CIGTS and MD slope (0.98 and 0.91) were
significantly (P < 0.001 for both) lower than in moderate
glaucoma (1.0 for both). There were no significant differences
for hit rate and correct rejection rate for all other pairs not
mentioned herein. Although the performance of the archetype
method decreased with respect to glaucoma severity, the mean
of hit rate and correct rejection rate by the archetype method
was still significant higher (P < 0.001) than all of the four
existing methods (Supplementary Fig. S3).
Figure 5A shows a representative example of clinician-
judged progression that was detected by both the archetype
method and three (CIGTS, MD slope, and PoPLR) of the four
existing progression detection methods. Archetype 13 (the
inferior altitudinal defect) was detected to be progressed with
a worsening rate of 0.06 per year, and this eye was determined
to be progressed by both trend (worsening of MD as well as
inferior paracentral and inferior region) and event (develop-
ment of an inferior temporal wedge defect) based on clinician
assessment. Figure 5B shows a representative nonprogressing
example by clinician evaluation but was determined as
progression by the archetype method. Yet, all four existing
progression detection methods did not find progression. The
worsening of archetype 9 (the inferior-temporal defect) with a
rate of 0.03 per year triggered the progression designation. The
clinicians agreed that the inferior region had been affected in
the VF series but judged no progression based on the final VF,
which had no event of worsening compared with baseline.
Figure 6 shows representative examples of clinician-
assessed progressions that were detected only by the
FIGURE 2. (A) The percentage of eyes with different number of
progression patterns. (B) The percentage of eyes with different
archetypes progressed. Black cross denotes the nine most frequently
progressed archetypes.
FIGURE 3. The kappa agreements between the clinician evaluation and
progression detection algorithms with clinician assessment as refer-
ence standard.
AI Approach to Detect Visual Field Progression in Glaucoma IOVS j January 2019 j Vol. 60 j No. 1 j 369
Downloaded from iovs.arvojournals.org on 02/06/2019
archetype method but not by AGIS, CIGTS, MD slope, and
PoPLR. The first example shows a progressed inferonasal step
pattern of archetype 5 at 0.06 per year, which was consistent
with clinician assessment of worsening of the inferonasal
region by trend (Fig. 6A). The second example was determined
as progressed superior paracentral defect of archetype 14 at
0.03 per year and was assessed as event-based progression in
the superior paracentral and superonasal regions by clinicians
(Fig. 6B). There were no VF series that were assessed as
nonprogressing by clinicians, nonprogressing by the archetype
method but progressing by most of the existing methods, as
indicated by high correct rejection rate (0.98–1.00) for three of
the four existing methods.
DISCUSSION
We developed a new method to track VF pattern progression
based on archetypal analysis, an unsupervised artificial
intelligence method. Compared with existing approaches,
our method provides not only progression status but also
quantifies progressed patterns. By decomposing the VF series
into 16 archetypes that were identified from a large dataset40
and subsequently validated in a prior clinical correlation
study,42 progression was detected by regressing the archetype
coefficients over time. Tested with 11,817 eyes from the
method development cohort, the archetype method was in fair
agreement with the existing methods of CIGTS (0.22), MD
slope (0.37), and PoPLR (0.33). All P values of kappa
coefficients were <0.001. A group of 397 eyes separate from
the 11,817 eyes were subsequently graded by glaucoma
specialists based on clearly defined criteria, which differed
from the method used by archetypal analysis. The clinician
evaluation was used as the reference standard to evaluate the
accuracy of our archetype method. The overall accuracy (mean
of hit rate and correct rejection rate) of the archetype method
(0.77) significantly (P < 0.001) outperformed the AGIS (0.52),
CIGTS (0.59), MD slope (0.59), and PoPLR (0.60) methods.
Interestingly, despite the different characteristics between
training and validation datasets (Table), the archetype method
still outperformed the four existing methods for progression
detection.
The threshold for progression detection was calculated as
the absolute average of the lower and upper tails, because even
if VF loss progresses, some individual archetypes can regress,
as all 16 archetype decomposition coefficients sum to 1, as
constrained by the archetype algorithm. For the example, as
shown in Figure 5A, as the initial inferonasal step progressed
into an inferior altitudinal defect, archetype 13 (inferior
altitudinal defect) had a positive slope (0.06/y), whereas
archetype 10 (inferonasal defect) had a negative slope
(0.06/y). This was determined to be progressing per the
archetype method, and worsening of the inferonasal region by
trend per the clinician assessment. Hence, the definition of a
significant slope is defined as an average of the left 2.5%
percentile and right 2.5% percentile.
Using subjective clinician assessment as a reference
standard can overestimate or underestimate the performance
of progression detection algorithms. However, clinician
assessment has been widely used as a reference standard to
evaluate progression algorithms in previous studies.15,36,52 We
used clearly defined criteria for clinician assessment to increase
reproducibility of our results in future studies. We did note that
our archetype method had a lower correct rejection rate than
the existing four methods. Admittedly, the performance of all
computer algorithms including the archetype method is not
ideal; nonetheless, the information of quantified VF pattern
changes over time can be used by clinicians in their own
FIGURE 4. The (A) hit rate, (B) correct rejection rate, and (C) mean of
hit rate and correct rejection rate of each progression detection
algorithm with clinician evaluation as reference standard.
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FIGURE 5. (A) A representative example of clinician-adjudged progression that was detected by both AT progression and most of the four existing
progression detection methods, and (B) a representative example of clinician-adjudged nonprogressing that was designated as progression by our
AT progression method but judged by all of the four existing progression detection methods as nonprogressing. All VFs are total deviation plots.
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decision-making process for assessing progression, especially
because the archetype method will highlight regions that are
worsening.
As shown in Figure 2B, the nine most frequently progressed
patterns include substantially decreased of the normal arche-
type 1 and increased in the abnormal archetypes 2, 3, 5, 6, 7, 8,
13, and 14. Although 63.7% of progressed eyes had substan-
tially decreased archetype 1, many of those eyes also had
accompanied substantially increased abnormal archetypes
(archetypes 2 to 16). When we excluded archetype 1 in the
VF progression algorithm, the progression prevalence de-
creased to 24.5% from 35.0%. For the 397 eyes clinically
assessed, the hit rate significantly (P < 0.001) decreased from
0.66 to 0.45, and the correct rejection rate significantly (P <
0.001) increased from 0.82 to 0.93, when not using archetype
1 for progression detection. These results suggest that
excluding archetype 1 for progression detection will improve
correct rejection rate but at the expense of a reduced hit rate.
As in the Ocular Hypertension Treatment Study (OHTS),41 this
is an analysis in which patients develop pathology other than
glaucoma, including cataract, posterior capsular opacity after
cataract surgery, macular disease, and higher visual pathway
lesions. In OHTS, a manual approach of stratifying VF loss
included glaucomatous and nonglaucomatous patterns. The
method we propose should not be construed as a method to
detect glaucomatous progression. Additional future work with
FIGURE 6. Representative examples of clinician-adjudged progressions that were detected only by AT progression but not by AGIS, CIGTS, MD
slope, and PoPLR: (A) progressed nasal step pattern of AT 5 and (B) progressed superior central detect of AT 14. All VFs are total deviation plots.
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the archetype method will be needed to better differentiate
glaucomatous progression from nonglaucomatous VF deterio-
ration.
The progression detection sensitivities of the four existing
methods in this work were substantially lower compared with
a previous study also using clinician assessment as the
reference standard,15 whereas the specificities were compara-
ble. In the work by Heijl and coworkers,15 the hit rates of AGIS
and CIGTS were 58% and 75%, respectively, compared with the
5% and 20% hit rate of AGIS and CIGTS in the clinical validation
cohort of our study. A possible reason might be the
considerably smaller number of VF follow-ups in our study:
mean VF number for each eye of 6 compared with 25 and 22
for the progressing and nonprogressing groups, respectively, in
the study by Heijl and coworkers.15
The low hit rate/high correct rejection rate of the existing
algorithms provides ample room for improvement in terms of
detecting VF progression. The rate of VF progression with the
clinical method (33%) was higher than any of the conventional
methods and in line with the archetype method (35%) using an
independent dataset. Yet the clinical method used in this study
was also somewhat arbitrary and would be time-consuming to
perform in the clinical setting.
Several previous works have applied unsupervised artificial
intelligence methods, including principal component analysis
and independent component analysis, to detect progression by
tracking change of VF patterns over time.35–37,53 It has been
reported that this type of artificial intelligence approach was
able to detect progression accurately.36,37,53 Compared with
previous approaches for detecting progression of patterns by
artificial intelligence methods, our archetype method provides
quantitative progression patterns of VF loss; these patterns
resemble clinically recognizable VF defects in glaucoma and
were clinically validated,42 thus are more interpretable and
assessable by clinicians. It is worth noting that our reference
standard of clinician’s progression assessment was determined
purely based on VF data, whereas in the previous work of
detecting progression by pattern analysis, the reference
standard of progression was determined by inspection of serial
stereoscopic optic nerve images.36 The difference in reference
standard might explain their higher overall accuracy of
progression detection, especially for the PoPLR method, also
performed better in their dataset than in our validation dataset.
This study has limitations. First, we used the average of the
absolute values of 2.5% and 97.5% percentiles of slope
distribution over clinical patient data as thresholds for
progression detection. Ideally, slope thresholds should be
based on the percentiles of slope distribution over healthy
subjects. As shown in Supplementary Table S1, the variation
ranges in rates of change for different archetypes were quite
different. Currently, we used a uniform threshold for all
archetypes to determine VF progression, which might not be
optimal. The normal limit thresholds for each archetype slope
may be dependent on the initial VF severity or the archetype
representation at the initial VF. We will try to address this
limitation in our future work. Second, using linear slope to
detect progression might not be optimal, as VF progression is
not linear, especially at early and end stages.54,55 In future
studies, sigmoid or other nonlinear regression methods could
be used to model the pattern-changing rates over time.54,55
Third, the glaucoma progression analysis (GPA) method for
progression detection was not included in our work for
comparison purpose, because this method is proprietary and
we were unable to obtain GPA datasets for this study. Fourth,
the reference standard in this work was established based on
the clinical evaluations by three glaucoma specialists without
consulting any other clinical data. In future studies, larger
numbers and different groups of clinicians might evaluate our
archetype method, especially in context of other clinical and
structural optic nerve data. Also, VF series repeated within a
short time range can be used as the reference for non-
progression, but was not available for this study.56 Fifth, for
each VF series, the clinician assessment in this study was
performed only once, whereas in clinical practice the clinician
assessment is performed repeatedly over the course of follow-
ups. In our future study, cumulative performance will be
evaluated for our archetype method compared with other
existing methods of progression detection.
In summary, we developed a new method to detect VF
progression in glaucoma by quantifying the changing of VF
patterns, identified by archetypal analysis, an unsupervised
artificial intelligence method. Our method was developed on a
large patient dataset from five glaucoma services and validated
based on 400 eyes graded by clinicians, and was proven to be
superior than four typical existing methods of progression
detection. The quantified information of VF pattern changes
over time and progression likelihood can be incorporated into
the decision-making process of clinicians to yield more
accurate clinical diagnosis of glaucoma progression.
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